Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lymphoma, T-Cell, Cutaneous 2Lymphoma 2Sezary Syndrome 1Mycosis Fungoides 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Tamoxifen 5Specimen Handling 4Radiotherapy 3Chemotherapy, Adjuvant 2Biopsy 2pembrolizumab 1exemestane 1Watchful Waiting 1Therapeutics 1Sulindac 1Radiation 1Psychiatric Rehabilitation 1Omacor 1Observation 1Norethindrone Acetate 1Neoadjuvant Therapy 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Letrozole 1Hypnosis 1High-Energy Shock Waves 1Gene Expression Profiling 1Fulvestrant 1Estradiol 1Early Intervention, Educational 1Docosahexaenoic Acids 1Bexarotene 1Atorvastatin 1Anastrozole 1Analgesia 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Breast Carcinoma In Situ × Bexarotene × Clear all
NCT03323658 2023-01-10

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled 12 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡